Grand Rounds Prompt: Alzheimer's Disease Treatment and Trials

Question: "What are the latest advancements in disease-modifying therapies for Alzheimer's, and how do anti-amyloid treatments like Aducanumab and Lecanemab impact disease progression and patient outcomes? Also, where can patients find ongoing clinical trials for these treatments?" Importance: Alzheimer's disease remains a major health challenge, and recent FDA approvals of anti-amyloid therapies have provided new hope for slowing disease progression. However, these treatments, such as Aducanumab, Lecanemab, and Donanemab, come with potential side effects like ARIA (Amyloid-Related Imaging Abnormalities). It's crucial to understand the risks, benefits, and the real-world implications of these therapies, along with opportunities for patient enrollment in clinical trials. Objective: To explore the effectiveness and risks of disease-modifying therapies for Alzheimer's disease, and identify ongoing clinical trials or programs offering access to these treatments. Points to Consider: - The mechanism by which anti-amyloid therapies slow Alzheimer's disease progression. - Safety concerns related to treatments like ARIA and the need for careful patient selection. - How physicians and patients can locate clinical trials for these disease-modifying therapies.